Companies in #Antibody-Drug Conjugates

ADC Therapeutics is a commercial-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for the treatment of hematologic cancers and solid tumors. Its lead product Zynlonta (loncastuximab tesirine) is the first CD19-targeted ADC approved for relapsed/refractory diffuse large B-cell lymphoma. The company is advancing a pipeline of next-generation ADCs targeting both hematologic malignancies and selected solid tumors.

ALX Oncology Holdings is a clinical-stage biotechnology company based in South San Francisco that engineers therapies designed to help the immune system fight cancer. Its lead asset, evorpacept, is a CD47-blocking fusion protein pairing a high-affinity SIRPalpha domain with an inactive Fc region, developed to relieve the 'don't eat me' signal that tumour cells use to evade macrophage clearance and to be combined with antibody-based regimens. The company is running biomarker-selected mid-stage programmes in HER2-positive gastric and gastroesophageal junction cancer and HER2-positive breast cancer, and is advancing ALX2004, an EGFR-targeted antibody-drug conjugate, in EGFR-expressing solid tumours. ALX Oncology has no approved products or product revenue and funds operations from its cash balance and public equity markets; it has traded on the Nasdaq Global Select Market under the ticker ALXO since its 2020 initial public offering and closed below $1.00 for the first time on October 13, 2026, versus a 52-week range of $1.05 to $2.66.

ArriVent BioPharma, Inc. is a clinical-stage oncology company developing differentiated medicines for cancers with high unmet need. Its lead candidate, firmonertinib, is an oral, brain-penetrant EGFR inhibitor licensed from Shanghai Allist Pharmaceuticals and evaluated in the global pivotal FURVENT and ALPACCA studies in EGFR-mutant non-small-cell lung cancer; the company is also building a pipeline of next-generation antibody-drug conjugates. ArriVent went public on Nasdaq in February 2024 at $16.00 per share and reported $373.1 million in cash, cash equivalents and investments as of June 30, 2026, a runway it guides into 2028. In October 2026 the company disclosed that the Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC did not meet its primary endpoint.

Firefly Bio is a clinical-stage bioconjugate and antibody-drug conjugate (ADC) company leveraging chemistry pioneered by Nobel laureate Carolyn Bertozzi to develop next-generation ADCs targeting KRAS-mutant and other solid tumors. Its lead programs combine site-specific bioconjugation with tumor-selective payload chemistries designed to widen the therapeutic index versus first-generation ADC platforms.

Lonza Group AG is a Swiss multinational CDMO and contract manufacturing organization serving the pharmaceutical, biotech, and nutrition industries. In 2026 the company is expanding its antibody-drug conjugate (ADC) manufacturing capacity and broadening collaborations with US biopharma drug developers, with a focus on integrated biologics and small-molecule services.

Pyxis Oncology is a clinical-stage company developing next-generation antibody-drug conjugates and immunotherapies for difficult-to-treat solid tumors. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an antibody-drug conjugate that targets extradomain-B fibronectin, a structural component of the tumor extracellular matrix rather than a surface antigen on the cancer cell itself; it holds FDA Fast Track designation and is being evaluated in Phase 1 monotherapy cohorts and in a Phase 1/2 combination study with Merck's pembrolizumab, with recurrent and metastatic head and neck squamous cell carcinoma the focus indication. A portfolio prioritization narrowed development onto that lead program. Founded in 2018 as a spinout of Longwood Fund with an early licensing relationship with Pfizer, and headquartered in Boston, Massachusetts, the company went public on Nasdaq in October 2021. It remains pre-revenue and funds development from the balance sheet: on September 30, 2026 it priced a registered public offering of 36,047,919 common shares, or pre-funded warrants in lieu, paired with warrants for expected gross proceeds of approximately $110 million and up to $282.6 million if the accompanying warrants are exercised in full.

Clinical-stage biotechnology company developing first-in-class MUC1-C-targeted immuno-oncology therapeutics along with diagnostics and formulations for endocrine disorders. Its lead antibody-drug conjugate XYA02 has FDA orphan drug designation in gastric cancer and dosed its first patient in September 2026.